Work Group and Evidence Review Team Membership. K/DOQI clinical practice guidelines on chronic kidney disease. Am J Kidney Dis. 2002;39(2 Suppl 1):S11–2.

Google Scholar 

Maclsaac RJ, Ekinci E. Progression of diabetic kidney disease in the absence of albuminuria. Diab Care. 2019;42:1842–4.

Article  Google Scholar 

Hanafusa N, Abe N, Joki N, Hoshino J, Taniguchi M, Kikuchi K, Hasegawa T, Goto S, Ogawa T, Kanda E, Nakai S, Naganuma T, Miura K, Wada A, Takemoto Y. 2021 annual dialysis data report, JSDT renal data registry. Nihon Toseki Igakkai Zasshi. 2022;55:665–723.

Article  Google Scholar 

Kengne AP, Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Gu DF, Suh I, Woodward M. Systolic blood pressure, diabetes and the risk of cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25:1205–13.

Article  PubMed  CAS  Google Scholar 

Edited and Authored by the Japan Diabetes Society: Japanese Clinical Practice Guidelines for Diabetes 2024. Tokyo: Nankoudo; 2024.

Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortarity for men screened in the multiple risk factor intervention trial. Diab Care. 1993;16:434–44.

Article  CAS  Google Scholar 

Iseki K, Oshiro S, Tozawa M, Ikemiya Y, Fukiyama K, Takishita S. Prevalence and correlates of diabetes mellitus in a screened cohort in Okinawa. Japan Hypertens Res. 2002;25:185–90.

Article  PubMed  Google Scholar 

Patel A, Macmahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effect of the fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet. 2007;370:829–40.

Article  PubMed  CAS  Google Scholar 

Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.

Article  PubMed  Google Scholar 

Kudo N, Yokoikawa H, Fukuda H, Sanada H, Miwa Y, Hisaoka T, Isonuma H. Achievement of target blood pressure levels among Japanese workers with hypertension and healthy lifestyle characteristics associated with therapeutic failure. PLoS ONE. 2015;10(7): e0133641.

Article  PubMed  PubMed Central  Google Scholar 

Ito S, Shikita K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria. Clin J Am Soc Nephrol. 2019;14:11161–72.

Google Scholar 

Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572–81.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Uchida HA, Nakajima H, Hashimoto M, Nakamura A, Nunoue T, Murakami K, Hosoya T, Komoto K, Taguchi T, Akasaka T, Shiosakai K, Sugimoto K, Wada J. Efficacy and safety of esaxerenone in hypertensive patients with diabetic kidney disease: a multicenter, open-label Prospective Study. Adv Ther. 2022;39:5158–75.

PubMed  PubMed Central  CAS  Google Scholar 

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.

Article  PubMed  CAS  Google Scholar 

Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M, Takagi H, Kawai K. The status of diabetes control and antidiabetic drug therapy in Japan—a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diab Res Clin Pract. 2006;73(2):198–204.

Article  Google Scholar 

Sato D, Sato Y, Masuda S, Kimura H. Effects of a sitagliptin safety on prescription behavior for oral antihyperglycemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan. Drug Saf. 2013;36:605–15.

Article  PubMed  CAS  Google Scholar 

Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128–39.

Article  PubMed  CAS  Google Scholar 

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant. 2004;19:2784–8.

Article  PubMed  Google Scholar 

Yokoyama H, Araki S, Honjo J, Okizaki S, Yamada D, Shudo R, Shimizu H, Sone H, Moriya T, Haneda M. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care. 2013;36:3227–33.

Article  PubMed  PubMed Central  Google Scholar 

Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K, Kanasaki MC, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes. 2007;56:1727–30.

Article  PubMed  CAS  Google Scholar 

Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25(5):514–23.

Article  PubMed  CAS  Google Scholar 

Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–63.

Article  PubMed  CAS  Google Scholar 

Barkis GL, Weir MR. Initial drops in glomerular filtration rate with certain drug classes retard kidney disease progression. Am J Nephrol. 2022;53:513–5.

Article  Google Scholar 

Kallistratos MA, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des. 2018;24(46):5537–41.

Article  PubMed  CAS  Google Scholar 

Provenzano M, Puchades MJ, Garofalo C, Jongs N, D’Marco L, Andreucci M, Nicola LD, Gorriz JL, Heerspink HJL. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J Am Soc Nephrol. 2022;33(8):1569–80.

Article  PubMed  PubMed Central  CAS  Google Scholar